Australia markets closed

GeoVax Labs, Inc. (GOVX)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
2.0000+0.1000 (+5.26%)
At close: 04:00PM EDT
1.9300 -0.07 (-3.50%)
After hours: 07:56PM EDT
Full screen
Loading interactive chart…
  • GlobeNewswire

    GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

    ATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief Scientific Officer, Mark Newman, PhD, will present data on GEO-CM04S1, the Company’s next-generation Covid-19 vaccine candidate, during the upcoming 24th Annual World Vaccine Congress taking place in Washington, DC on April 1-4, 2024. Presentation Details:Present

  • GlobeNewswire

    GeoVax to Present at the 36th Annual Roth Conference

    ATLANTA, GA, March 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 36th Annual Roth Conference, taking place in Dana Point, CA on March 17-19, 2024. Presentation Details: Presenter: David Dodd, Chairman & CEODate/Time: March 18, 2024, 2:30 pm PTLocation: Dana Point, CAWebcast Link: Ro

  • GlobeNewswire

    GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System

    Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines ATLANTA, GA, March 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced a significant milestone toward implementation of a validated chicken embryonic fibroblast (CEF) based production system for the company’s MVA-based vaccines, with the relea